While other technologies use mathematical extrapolations combining both independent and therapy system log data to achieve QA, Delta4 Phantom+ and Delta4 Discover provide complete and exact independent measurements. "Express Measure," a feature of Delta4 Discover, is the first in-vivo dosimetry system that independently verifies Machine Output, Gantry Angle, Collimator Angle, MLC (Multileaf Collimator) and Patient Position for all fractions of complex radiation therapies, expediting QA workflow.
"We are pleased to introduce Delta4 Synthesis to the attendees at ASTRO," commented ScandiDos CEO Görgen Nilsson. "Our system addresses the principal needs of our stakeholders by saving treatment set-up and clinic preparation time for physicists and providing radiologists with the assurance of the delivered dose, from prescription to final fraction, ultimately providing the most accurate plan verification and QA."
About ScandiDos AB
ScandiDos AB is a worldwide leader in the development of advanced dosimetry and QA (Quality Assurance) products that ensure radiation doses in advanced cancer radiation therapies are delivered to the patient in the quantity and manner intended. The company's measurement systems and software are designed to meet QA requirements and provide validation for new cancer radiation treatments being implemented in clinics around the world.
ScandiDos was founded in 2002 and is headquartered in Uppsala, Sweden. The company operates worldwide, with a U.S. office in Madison, WI and international offices in Beijing and Paris. ScandiDos has installed its dosimetry and QA solutions in 45 countries and its systems can be found in well-known cancer centers throughout the United States. Since April 2014, ScandiDos has been listed on NASDAQ First North Stockholm with the ticker symbol SDOS.
Office: +1-212-583-1043 Ext. 207
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/scandidos-unveils-delta4-synthesis-at-astro-annual-meeting-in-boston-300330851.html